Shots: Dyno to receive upfront, research funding, license fees, clinical, regulatory & sales milestones and royalties on WW sales. The company will also utilize its AI technology & its suite […]readmore
Tags : Novartis
1.Fitbit Launches Heart Study to Validate its Wearable Technology for Identifying Atrial Fibrillation Published: May 06, 2020 | Tags: Fitbit, Launches, Heart Study, Validate, Wearable Technology, Identifying, Atrial Fibrillation 2. […]readmore
Shots: The approval is based on P-II GEOMETRY mono-1 study assessing Tabrecta (400mg, bid) in 97 patients with metastatic NSCLC harboring mutations that lead to METex14. The US FDA approved the […]readmore
WuXi Biologics and Aravive Collaborate to Develop Novel High-Affinity Bispecific Antibodies for Cancer and Fibrosis Published: Apr 30, 2020 | Tags: WuXi Biologics, Aravive, Collaborate, Develop, Novel, High-Affinity Bispecific Antibodies, Cancer, […]readmore
Pharma
Regulatory
Novartis’ Enerzair Breezhaler (QVM149, IND/GLY/MF) Receives CHMP’s Recommendation for Approval
Shots: The CHMP’s recommendation is based on P-III IRIDIUM study assessing IND/GLY/MF (150/50/160 μg & 150/50/80 μg) vs IND/MF doses (150/320 μg & 150/160 μg) in 3,092 patients in a […]readmore
Shots::stohthShots: Novartis to initiate P-III CAN-COVID study assessing the efficacy of canakinumab vs PBO on top of SOC in patients with COVID-19 pneumonia with its anticipated results in late summer […]readmore
Regulatory
Novartis’ Cosentyx (secukinumab) Receives EC’s Approval for Axial Spondyloarthritis Spectrum
Shots: The approval is based on P-III PREVENT study involve assessing Cosentyx (150mg, SC with loading dose and 150mg with no loading dose) vs PBO in 555 adult patients with […]readmore
1. Sanofi Receives the US FDA’s Approval for its MenQuadfi Meningococcal (MenACWY) Conjugate Vaccine Published: Apr 23, 2020 | Tags: Sanofi, Receives, US, FDA, Approval, MenQuadfi, Meningococcal, MenACWY, Conjugate Vaccine 2. […]readmore
The global biopharma companies are developing novel therapies & devices which is, in turn, enhancing their portfolio and encouraging them in this undergoing competition to stay in the topmost position […]readmore
Regulatory
Novartis’ Kymriah (tisagenlecleucel) Receives the US FDA’s Regenerative Medicine Advanced
Shots: Shots: The US FDA has granted RMAT designation to Novartis’ Kymriah (tisagenlecleucel) to treat patients with r/r FL. The designation is based on P-II ELARA study evaluating the efficacy […]readmore